Perrigo labeling deferrals
This article was originally published in The Tan Sheet
Executive Summary
FDA grants private labeler's request for varying deferral dates from OTC labeling final rule, depending on when agency labeling templates become available (1"The Tan Sheet" Oct. 1, p. 3). In Dec. 11 letter, FDA concludes that based on amount of time it has taken to finalize labeling templates for several ANDA drug products, "we consider your timetable for concurrent implementation of labeling revisions for [these] products to be appropriate." Implementation deferrals apply to clemastine fumarate tablets, doxylamine succinate tablets, pseudoephedrine HCl extended release and minoxidil topical solution, all of which did not have finalized FDA labeling templates as of Oct. 1...
You may also be interested in...
FDA "Drug Facts" Templates Supersede Reference Listed Drug Labeling - FDA
Generic drugs approved under ANDAs may conform to "Drug Facts" labeling as it appears in templates posted on FDA's Web site without having to wait for the reference listed drug's labeling to be approved.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.